Literature DB >> 24576534

Heteroresistance of Helicobacter pylori from the same patient prior to antibiotic treatment.

Cheng-Yen Kao1, Ai-Yun Lee2, Ay-Huey Huang3, Pin-Yi Song4, Yao-Jong Yang5, Shew-Meei Sheu6, Wei-Lun Chang6, Bor-Shyang Sheu6, Jiunn-Jong Wu7.   

Abstract

Antibiotic resistance among Helicobacter pylori strains has been increasing worldwide and has affected the efficacy of current treatments. The aim of this study was to evaluate whether treatment failure was due to the presence of antibiotic-susceptible and -resistant H. pylori simultaneously within the same host before eradication. In order to discover H. pylori with antibiotic heteroresistance in the same patient, we examined the antibiotic susceptibility of H. pylori isolated from 412 patients without H. pylori eradication. The E-test was used to determine the minimal inhibitory concentration of these strains. The results showed 19 (4.6%) of patients harbored antibiotic heteroresistant H. pylori, resistant to levofloxacin (5/19), clarithromycin (1/19) and metronidazole (16/19). Among them, three patients' isolates showed heteroresistance to two antibiotics. The genetic diversity of each isolate was evaluated by random amplified polymorphic DNA PCR and the results showed that only 1 patient' isolate (5.3%) had a different pattern while the others showed identical or similar fingerprinting patterns. Mutations in the genes responsible for antibiotic resistance were investigated by direct sequencing and compared between strains within each pair. All 5 levofloxacin-resistant isolates had mutations in GyrA at the QRDR region (N87 or D91). Strain 1571R with clarithromycin resistance had a A2042G substitution in its 23S rRNA. There were 15 metronidazole-resistant strains (100%) with isogenic variation of RdxA, and 6 strains (40%) contained FrxA variation (excluded pair 1159). These results suggest that the treatment failure of heteroresistant H. pylori mostly develops from high genomic variation of pre-existing strains through long term evolution rather than mixed infection with different strains.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibiotic; Helicobacter pylori; Heteroresistance; Treatment failure

Mesh:

Substances:

Year:  2014        PMID: 24576534     DOI: 10.1016/j.meegid.2014.02.009

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  19 in total

Review 1.  Antimicrobial heteroresistance: an emerging field in need of clarity.

Authors:  Omar M El-Halfawy; Miguel A Valvano
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

2.  A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.

Authors:  Feng-Woei Tsay; Deng-Chyang Wu; Hsien-Chung Yu; Sung-Shuo Kao; Kung-Hung Lin; Jin-Shiung Cheng; Huay-Min Wang; Wen-Chi Chen; Wei-Chih Sun; Kuo-Wang Tsai; Ping-I Hsu
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

3.  Droplet Digital PCR-Based Detection of Clarithromycin Resistance in Helicobacter pylori Isolates Reveals Frequent Heteroresistance.

Authors:  Lu Sun; Sarah Talarico; Lena Yao; Lihua He; Steve Self; Yuanhai You; Huifang Zhang; Yiyao Zhang; Yongjun Guo; Guodong Liu; Nina R Salama; Jianzhong Zhang
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

4.  Direct detection of Helicobacter pylori in biopsy specimens using a high-throughput multiple genetic detection system.

Authors:  Yanmei Zhang; Shiwen Wang; Binjie Hu; Fuju Zhao; Ping Xiang; Danian Ji; Fei Chen; Xiaoli Liu; Feng Yang; Yong Wu; Mimi Kong; Li Nan; Yingxin Miao; Wenrong Jiang; Yi Fang; Jinghao Zhang; Zhijun Bao; Michal A Olszewski; Hu Zhao
Journal:  Future Microbiol       Date:  2016-09-06       Impact factor: 3.165

Review 5.  Underscoring interstrain variability and the impact of growth conditions on associated antimicrobial susceptibilities in preclinical testing of novel antimicrobial drugs.

Authors:  David A Sanchez; Luis R Martinez
Journal:  Crit Rev Microbiol       Date:  2018-12-06       Impact factor: 7.624

6.  Antibiotic failure mediated by a resistant subpopulation in Enterobacter cloacae.

Authors:  Victor I Band; Emily K Crispell; Brooke A Napier; Carmen M Herrera; Greg K Tharp; Kranthi Vavikolanu; Jan Pohl; Timothy D Read; Steven E Bosinger; M Stephen Trent; Eileen M Burd; David S Weiss
Journal:  Nat Microbiol       Date:  2016-05-09       Impact factor: 17.745

Review 7.  Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications.

Authors:  Evariste Tshibangu-Kabamba; Yoshio Yamaoka
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-05-17       Impact factor: 46.802

8.  Impacts of H. pylori mixed-infection and heteroresistance on clinical outcomes.

Authors:  Masoud Alebouyeh; Abbas Yadegar; Nastaran Farzi; Marzyieh Miri; Homayoon Zojaji; Somayeh Gharibi; Zeinab Fazeli; Naser Ebrahimi Daryani; Hamid Asadzadeh Aghdaei; Mohammad Reza Zali
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2015

9.  Detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones in Brazil: A national survey.

Authors:  Bruno Squarcio Sanches; Gustavo Miranda Martins; Karine Lima; Bianca Cota; Luciana Dias Moretzsohn; Laercio Tenorio Ribeiro; Helenice P Breyer; Ismael Maguilnik; Aline Bessa Maia; Joffre Rezende-Filho; Ana Carolina Meira; Henrique Pinto; Edson Alves; Ramiro Mascarenhas; Raissa Passos; Julia Duarte de Souza; Osmar Reni Trindade; Luiz Gonzaga Coelho
Journal:  World J Gastroenterol       Date:  2016-09-07       Impact factor: 5.742

10.  Efficacy of Clarithromycin Depends on the Bacterial Density in Clarithromycin-Heteroresistant Helicobacter pylori Infections: An In Situ Detected Susceptibility and Quantitative Morphometry-Based Retrospective Study.

Authors:  Jewel Ju Ea Kim; Ildikó Kocsmár; György Miklós Buzás; Ildikó Szirtes; Orsolya Rusz; Csaba Diczházi; Attila Szijártó; István Hritz; Zsuzsa Schaff; András Kiss; Éva Kocsmár; Gábor Lotz
Journal:  Pathol Oncol Res       Date:  2021-06-29       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.